Repositioning Candidate Details

Candidate ID: R0449
Source ID: DB01210
Source Type: approved
Compound Type: small molecule
Compound Name: Levobunolol
Synonyms: (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; Levobunolol
Molecular Formula: C17H25NO3
SMILES: CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O
Structure:
DrugBank Description: A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
CAS Number: 47141-42-4
Molecular Weight: 291.3853
DrugBank Indication: For lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
DrugBank Pharmacology: Levobunolol is an ophthalmic beta-blocker, equally effective at β(1)- and β(2)-receptor sites. Levobunolol reduces both elevated and normal IOP in patients with or without glaucoma. In patients with elevated IOP, levobunolol reduces mean IOP by approximately 25-40% from baseline. As the drug is a nonselective &beta-adrenergic blocking agent, it can produce both systemic pulmonary and cardiovascular effects following topical application to the eye. These effects include adverse pulmonary effects (eg. bronchoconstriction, increased airway resistance), and a decrease in blood pressure and heart rate.
DrugBank MoA: Levobunolol's mechanism of action in reducing IOP is not clearly defined, but is believed to be due to a reduction of the production of aqueous humor via blockage of endogenous catecholamine-stimulated increases in cyclic adenosine monophosphate (AMP) concentrations within the ciliary processes.
Targets: Beta-2 adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist
Inclusion Criteria: Indication associated